Here are the 424B prospectus supplements from STERIS plc (STE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow STE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STE filings page.
STERIS plc, through its indirect wholly owned subsidiary STERIS Irish FinCo Unlimited Company, is offering $750,000,000 aggregate principal amount of 5.650% senior notes due 2033 and $750,000,000 of 5.875% senior notes due 2036. The notes are senior unsecured obligations, jointly and severally guaranteed on a senior unsecured basis by STERIS plc, STERIS Corporation and STERIS Limited. Interest is payable semiannually beginning June 15, 2027.
STERIS Corporation agreed to acquire Pennsylvania-based Xodus Medical, Inc. and related entities for $2.1 billion in cash, with additional earnout consideration of up to $150 million based on the Xodus business’s performance in calendar 2028. Completion is subject to customary conditions, including regulatory approvals, and was expected by December 31, 2026. The offering is not conditioned on closing. Absent a special mandatory redemption event, expected net proceeds of approximately $1,483 million after underwriting discounts and estimated expenses, together with delayed-draw borrowing and cash on hand, are intended to fund the purchase price, transaction expenses, general corporate expenses and working capital.
If the purchase agreement is terminated, or the acquisition is not completed by the later of January 11, 2028 and five business days after any mutually agreed extension, the notes must be redeemed at 101% of principal plus accrued and unpaid interest.
STERIS plc’s indirect subsidiary, STERIS Irish FinCo Unlimited Company, is offering two series of senior unsecured notes, guaranteed jointly and severally by STERIS plc, STERIS Corporation and STERIS Limited. The issuer intends to use the proceeds, together with delayed-draw borrowings and cash on hand, to fund STERIS Corporation’s proposed acquisition of Xodus and related expenses, general corporate expenses and working capital needs. The offering is not conditioned on completing the acquisition. If the purchase agreement is terminated or the acquisition misses its applicable deadline, the notes are subject to special mandatory redemption.